(Reuters) – The European Union’s drug regulator on Thursday approved a COVID-19 treatment from British-U.S. duo GSK and Vir Biotechnology and another from Swedish drugmaker Sobi, as the bloc builds its defences against Omicron.
(Reporting by Pushkala Aripaka and Amna Karimi in Bengaluru; Editing by Edmund Blair)
